According to the president of the fund behind Sputnik V, 71 nations with a combined population of four billion people have received the first Covid-19 injection ever documented in the globe.
Sputnik V has established itself as “one of the most efficient and secure instruments” against Covid-19 both in Russia and abroad in the two years after its registration, according to the president of the foundation that funded the vaccine’s research and is in charge of managing its distribution.
After acquiring the necessary paperwork from Russia’s Health Ministry, Sputnik V became the first vaccination against the new coronavirus to be registered in the whole globe on August 11, 2020.
Since that time, the Gamaleya Institute in Moscow, which developed the vaccine, “has become the most exported drug in Russia’s history and deservedly established itself as one of the most effective and safe tools to combat coronavirus infection in the world,” according to Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF).
“Sputnik V was trusted in 71 countries around the globe where more than 4 billion people reside,” he noted.
The RDIF organized mass manufacturing not just in Russia but also in 18 other nations, including Iran, India, China, Brazil, Argentina, and Argentina.
During the Russian immunization campaign, the two-component Sputnik V injection had a 97.6% effectiveness rate, according to statistics from the Gamaleya Institute and the Health Ministry.
The RDIF president said that data from national immunization programs in various parts of the world, including Europe, Asia, the Middle East, and Latin America, as well as the findings of more than 50 clinical investigations “proved” the vaccine’s efficacy.
The Lancet, Nature, Vaccines, Cell Reports Medicine, and other international peer-reviewed medical publications, he said, have published studies on the Russian vaccine.
“The vaccine not only helped protect people from the original coronavirus strain and bring down the peak of the disease, its proven universal platform of human adenoviral vectors has shown high efficiency in combating new mutations [of Covid-19], including the Delta and Omicron strains,” Dmitriev said.
A combined research by the Lazzaro Spallanzani National Institute for Infectious Diseases and the Gamaleya Institute, which was released in early 2022, “confirmed that Sputnik V gave the greatest immunity against Omicron,” he stated. The Russian jab is 2.6 times more effective against Omicron than the Pfizer injection manufactured in the US, among other things, according to that article.
In May 2021, a one-component Sputnik Light vaccination was also approved in Russia and thereafter distributed to more than 30 nations. According to the head of RDIF, it became a “universal booster for other vaccinations,” offering greater defense against the Omicron strain and other alterations.
However, the World Health Organization and the European Medicines Agency, the EU’s watchdog, have yet to approve Sputnik V and Sputnik Light (EMA). Russian officials have asserted that political factors are to blame for the delay. Following the beginning of Moscow’s military intervention in Ukraine in February, RDIF was also among the first Russian firms to be subject to Western sanctions.
“The epidemic should serve as a reminder to everyone in the human race that preserving lives requires cooperation and teamwork. Only by following this road will it be feasible to successfully combat present and potential risks, particularly epidemiological ones, Dmitriev said.
The source used in the creation of a news story: https://www.rt.com
